What’s New About the New US Obesity Guidelines?
- 354 Downloads
The health care industry in the US is awakening to the threat of a new most common cause of preventable death in the country being obesity, potentially overcoming deaths from tobacco at some point in the near future, although these statistics and their conclusions are hotly debated . Obesity prevalence has risen over the past 30 years purportedly due to excessive calorie intake and lack of physical activity. Part of the effort to combat this threat has been a call to arms by the American Medical Association who proclaimed obesity to be a disease in 2013 in part due to arguments and evidence summarized in the TOS White Paper published in 2008 . The simple outcome that ultimately was arrived upon after tackling a very difficult conceptual idea of disease is that obesity is a disease because it causes harm to the body. A disease should be treated and current treatment guidelines have been recently released in 2014 nicknamed the Obesity 2 Guidelines . These guidelines were...
KeywordsObesity Overweight Guidelines US
Caroline M. Apovian has received grant support from National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK073302, P30 DK046200, R01 DK080448, R01 AG037547, R24 DK094749, P01 HL081587).
Compliance with Ethics Guidelines
Conflict of Interest
Caroline M. Apovian reports personal fees for participating on Advisory Boards from Allergan, Inc., Orexigen Therapeutics, Johnson & Johnson Services, Inc., Merck & Co., Inc., Abbott Nutrition, Arena Pharmaceuticals, Amylin Pharmaceuticals, Novo Nordisk, Inc., NutriSystem, Inc., Sanofi-Aventis US, LLC, GI Dynamics, Inc., and Zafgen, grants from MetaProteomics, LLC, The Dr. Robert C. and Veronica Atkins Foundation, Sanofi-Aventis US, LLC, Pfizer, Inc., Aspire Bariatrics, Inc., GI Dynamics, Inc., Amylin Pharmaceuticals, and Orexigen Therapeutics, outside the submitted work.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
- 1.Hoerger T. Controversies in obesity mortality: a tale of two studies. RTI-UNC Center of Excellence in Health Promotion Economics. 2006;1:1–5.Google Scholar
- 2.TOS Obesity as a Disease Writing Group: David B. Allison(chair)1, Morgan Downey (co-chair) Richard L. Atkinson, Charles J. Billington, George A. Bray, Robert H. Eckel, Eric A. Finkelstein, Michael D. Jensen and Angelo Tremblay. Obesity as a disease: a white paper on evidence and arguments commissioned by the Council of the Obesity Society. Obesity. 2008. doi: 10.1038/oby.2008.231.
- 3.Jensen MD, Ryan DH, Donato KA, Apovian CM, Ard JD, Comuzzie AG, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Obesity. 2013. doi: 10.1002/oby.20660.PubMedCentralGoogle Scholar
- 6.Donnelly JE, Blair SN, Jakicic JM, Manore MM, Rankin JW, Smith BK, et al. American College of Sports Medicine Position Stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc. 2009;41(2):459–71.PubMedCrossRefGoogle Scholar